Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 5, 1999, Pages 5-13

  Calabrese, Joseph R ^a,b   Rapport, Daniel J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mood Disorders Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; IMIPRAMINE; LITHIUM;

AFFECTIVE NEUROSIS; ANALYTIC METHOD; COMORBIDITY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; HOSPITALIZATION; MANIC DEPRESSIVE PSYCHOSIS; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZATION; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REVIEW; SYMPTOMATOLOGY; SYSTEM ANALYSIS;

EID: 0032957187     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Bowden CL, Swann A, Calabrese JR, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium placebo study. Psychopharmacol Bull 1997;33:693-699
2. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970;2(7668):326-330
3. Melia PI. Prophylactic lithium: a double blind trial in recurrent affective disorders. Br J Psychiatry 1970;116:621-624
4. Coppen A, Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders: controlled trial. Lancet 1971;2(7719):275-279
5. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972;2:308-311
6. Hullin RP, McDonald R, Allsopp MNE. Further report on prophylactic lithium in recurrent affective disorders. Br J Psychiatry 1975;126:281-284
7. Stallone F, Shelley E, Mendlewicz J, et al. The use of lithium in affective disorders, III: a double blind study of prophylaxis in bipolar illness. Am J Psychiatry 1973;130:1006-1010
8. Prien RF, Caffey EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic depressive illness: report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973;28:337-341
9. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-425
10. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26:57-63
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Second Edition. Washington, DC: American Psychiatric Association; 1970
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association: 1980
13. Swann AC, Bowden CL, Morris D, et al. Depression during mania: effect on response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37-42
14. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5 year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-35
15. Goodwin FK, Jamison KR. Maintenance medical treatment. In: Manic Depressive Illness. Oxford, England: Oxford University Press; 1990:665-724
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
17. Fisher S, Lipman RS, Uhlenhuth EH, et al. Drug effects and initial severity of symptomatology. Psychopharmacologia 1965;7:57-60
18. Uhlenhuth EH, Matuzas W, Warner TD, et al. Methodological issues in psychopharmacological research: growing placebo response rate: the problem in recent therapeutic trials. Psychopharmacol Bull 1997;33:31-39
19. Post RM, Frye MA, Leverich GS, et al. The role of complex combination therapy in the treatment of refractory bipolar illness. CNS Spectrums 1998;3:66-86
20. Louis TA, Lavori PW, Bailar JC, et al. Crossover and self-controlled designs in critical research. N Engl J Med 1984;310:24-31
21. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
22. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry 1993;50:448-455
23. Mander AJ. Is there a lithium withdrawal syndrome? Br J Psychiatry 1986;149:498-501
24. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976;133: 925-929
25. Fyro B, Petterson U. A double-blind study of the prophylactic effect of lithium in manic depressive disease. Acta Psychiatr Scand 1977;262:17-22
26. Mendlewicz J. Lithium discontinuation in bipolar illness: a double blind prospective controlled study. In: Corsini GV, ed. Current Trends in Lithium and Rubidium Therapy. Lancaster, England: MTP Press; 1984:135-141
27. Markar HR, Mander AJ. Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry 1989;155:496-500
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
29. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435
30. Denicoff KD, Blake KD, Smith-Jackson EE, et al. Morbidity in treated bipolar disorder: a one year prospective study using daily life chart ratings. Depression 1994;2:95-104
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
32. Shapiro DR, Quitkin FM, Fleiss JL. Response to maintenance therapy in bipolar illness: effect of index episode. Arch Gen Psychiatry 1989;46: 401-405
33. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984;41:1096-1104
34. Pope HG, McElroy SL, Keck P, et al. Valproate in the treatment of acute mania: a placebo controlled study. Arch Gen Psychiatry 1991;48:62-68
35. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex and placebo in the treatment of mania. JAMA 1994;271:918-924
36. Sanger TM, Tohen M, Tollefson GD, et al. Olanzapine versus placebo in the treatment of acute mania. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Kamuela, Hawaii
37. Müller-Oerlinghausen B, Retzow A for the European Valproate Acute Mania Study Group. Valproate as an adjunct to neuroleptic medication in the treatment of acute episodes of mania. Presented at the 1998 annual meeting of the International Academy of Biomedical and Drug Research, Workshop on Novel Therapeutic Strategies in the Schizophrenic Spectrum and Mood Disorders. Venice, Italy
38. Goodwin FK, Jamison KR: Manic Depressive Illness. New York: NY: Oxford University Press; 1990:603-629
39. Keller MB, Lavori PW, Kane JM, et al. Subsyndromal symptoms in bipolar disorder: a comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992;49:371-376
40. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978;2:159-175
41. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66:211-217
42. Baastrup PC. The use of lithium in manic depressive psychosis. Compr Psychiatry 1964;5:396-408